Avanthika Venkatachalam - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Avanthika Venkatachalam

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Research Square|November 1, 2024

Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AMLBrian Ball, Wenbin Xiao, Gautam Borthakur, et al.

Journal of Hematology & Oncology|July 15, 2025

Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AMLBrian J Ball, Wenbin Xiao, Gautam Borthakur, et al.

Cell|August 28, 2018

Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical ModelsWaleed Minzel, Avanthika Venkatachalam, Avner Fink, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Research Square|November 1, 2024

Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AMLBrian Ball, Wenbin Xiao, Gautam Borthakur, et al.

Journal of Hematology & Oncology|July 15, 2025

Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AMLBrian J Ball, Wenbin Xiao, Gautam Borthakur, et al.

Cell|August 28, 2018

Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical ModelsWaleed Minzel, Avanthika Venkatachalam, Avner Fink, et al.

Pageof 2